CIDARA THERAPEUTICS INC (CDTX)
US1717571079 - Common Stock
Taking everything into account, CDTX scores 3 out of 10 in our fundamental rating. CDTX was compared to 588 industry peers in the Biotechnology industry. While CDTX seems to be doing ok healthwise, there are quite some concerns on its profitability. CDTX is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CDTX has reported negative net income.
CDTX had a negative operating cash flow in the past year.
In the past 5 years CDTX always reported negative net income.
CDTX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
CDTX's Return On Assets of -49.42% is in line compared to the rest of the industry. CDTX outperforms 50.86% of its industry peers.
CDTX's Return On Equity of -392.25% is on the low side compared to the rest of the industry. CDTX is outperformed by 77.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -49.42% | ||
| ROE | -392.25% | ||
| ROIC | N/A |
ROA(3y)-80.99%
ROA(5y)-78.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for CDTX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CDTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CDTX has more shares outstanding
Compared to 5 years ago, CDTX has more shares outstanding
CDTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 2.70 indicates that CDTX is not a great score, but indicates only limited risk for bankruptcy at the moment.
CDTX's Altman-Z score of 2.70 is fine compared to the rest of the industry. CDTX outperforms 76.20% of its industry peers.
There is no outstanding debt for CDTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.7 |
ROIC/WACCN/A
WACC9.33%
2.3 Liquidity
A Current Ratio of 1.62 indicates that CDTX should not have too much problems paying its short term obligations.
With a Current ratio value of 1.62, CDTX is not doing good in the industry: 81.16% of the companies in the same industry are doing better.
CDTX has a Quick Ratio of 1.55. This is a normal value and indicates that CDTX is financially healthy and should not expect problems in meeting its short term obligations.
CDTX has a Quick ratio of 1.55. This is amonst the worse of the industry: CDTX underperforms 80.99% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.62 | ||
| Quick Ratio | 1.55 |
3. Growth
3.1 Past
CDTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 29.09%, which is quite impressive.
Looking at the last year, CDTX shows a decrease in Revenue. The Revenue has decreased by -7.77% in the last year.
CDTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 45.39% yearly.
EPS 1Y (TTM)29.09%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-152.94%
Revenue 1Y (TTM)-7.77%
Revenue growth 3Y45.39%
Revenue growth 5YN/A
Revenue growth Q2Q-68.78%
3.2 Future
The Earnings Per Share is expected to grow by 25.60% on average over the next years. This is a very strong growth
CDTX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.12% yearly.
EPS Next Y34.83%
EPS Next 2Y-10.7%
EPS Next 3Y19.9%
EPS Next 5Y25.6%
Revenue Next Year-6.72%
Revenue Next 2Y-41.71%
Revenue Next 3Y-9.44%
Revenue Next 5Y12.12%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
CDTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CDTX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CDTX's earnings are expected to grow with 19.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.7%
EPS Next 3Y19.9%
5. Dividend
5.1 Amount
CDTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CIDARA THERAPEUTICS INC
NASDAQ:CDTX (4/26/2024, 7:00:02 PM)
After market: 12.7 +0.07 (+0.55%)12.63
-0.37 (-2.85%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.14B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -49.42% | ||
| ROE | -392.25% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.89
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.62 | ||
| Quick Ratio | 1.55 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)29.09%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y34.83%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-7.77%
Revenue growth 3Y45.39%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y